Effect of Preoperative Mitral Regurgitation on LVAD Outcomes in Patients with Elevated Pulmonary Vascular Resistance
Cardiovascular Drugs and Therapy · 2025
DOI: 10.1007/s10557-024-07581-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Drugs and Therapy, 2025. Verfasst von Riyad Yazan Kherallah und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA. Hauptthemen laut MEDLINE: Heart-Assist Devices, Mitral Valve Insufficiency, Vascular Resistance, Heart Failure. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: In patients with end-stage heart failure who undergo left ventricular assist device (LVAD) implantation, higher pulmonary vascular resistance (PVR) is associated with higher right heart failure rates and ineligibility for heart transplant. Concomitant mitral regurgitation (MR) could potentially worsen pulmonary hemodynamics and lead to worse outcomes; however, its effects in this patient population have not been specifically examined. METHODS: Using an institutional database spanning November 2003 to August 2017, we retrospectively identified patients with elevated PVR who underwent LVAD implantation. Patients were stratified by concurrent MR: moderate/severe (PVR + MR) vs. mild/none (PVR - MR). Cumulative incidence functions and Fine-Gray competing risk regression were performed to assess the effect of MR on heart transplant rates and overall survival during index LVAD support. RESULTS: Of 644 LVAD recipients, 232 (171 HeartMate II, 59 HeartWare, 2 HeartMate III) had baseline PVR > 3 Woods units; of these, 124 (53%) were INTERMACS 1-2, and 133 (57%) had moderate/severe MR (≥ 3 +). Patients with PVR + MR had larger a baseline left ventricular end-diastolic diameter than patients with PVR - MR (87.9 ± 38.2 mm vs. 75.9 ± 38.0 mm; P = 0.02). Median clinical follow-up was 18.8 months (interquartile range: 4.7-36.4 months). Moderate/severe MR was associated with lower mortality rates during index LVAD support (adjusted hazard ratio 0.64, 95% CI 0.41-0.98; P = 0.045) and higher heart transplant rates (adjusted odds ratio 2.86, 95% CI 1.31-6.25; P = 0.009). No differences in stroke, gastrointestinal bleeding, or right heart failure rates were observed. CONCLUSIONS: Among LVAD recipients with elevated preoperative PVR, those with moderate/severe MR had better overall survival and higher transplant rates than those with mild/no MR. These hypothesis-generating findings could be explained by incremental LVAD benefits resulting from reduction of MR and better LV unloading in a subset of patients with larger ventricles at baseline. In patients with preoperative elevated PVR, MR severity may be a prognostic sign that can inform patient selection for end-stage heart failure therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiology, Department of Medicine, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
- Division of Cardiothoracic Transplantation and Circulatory Support, Department of Surgery, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
- Department of Cardiology, The Texas Heart Institute, 6770 Bertner Avenue, Houston, TX, 77030, USA.
- Division of Cardiology, Department of Medicine, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA. Srikanth.koneru@bcm.edu.
- Department of Cardiology, The Texas Heart Institute, 6770 Bertner Avenue, Houston, TX, 77030, USA. Srikanth.koneru@bcm.edu.
ORCID-Profile: Harveen K Lamba, Andrew B Civitello, Ajith P Nair, Leo Simpson, Gabriel Loor, Joggy K George, Reynolds M Delgado, O H Frazier, Srikanth Koneru
Zitieren
APA
Kherallah, R. Y., Lamba, H. K., Civitello, A. B., Nair, A. P., Simpson, L., Shafii, A. E., Loor, G., George, J. K., Delgado, R. M., Liao, K. K., Stainback, R. F., Frazier, O. H., & Koneru, S. (2025). Effect of Preoperative Mitral Regurgitation on LVAD Outcomes in Patients with Elevated Pulmonary Vascular Resistance. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-024-07581-1
Vancouver
Kherallah RY, Lamba HK, Civitello AB, Nair AP, Simpson L, Shafii AE, et al. Effect of Preoperative Mitral Regurgitation on LVAD Outcomes in Patients with Elevated Pulmonary Vascular Resistance. Cardiovascular Drugs and Therapy. 2025. doi:10.1007/s10557-024-07581-1
BibTeX
@article{Kherallah2025,
author = {Kherallah, Riyad Yazan and Lamba, Harveen K and Civitello, Andrew B and Nair, Ajith P and Simpson, Leo and Shafii, Alexis E and Loor, Gabriel and George, Joggy K and Delgado, Reynolds M and Liao, Kenneth K and Stainback, Raymond F and Frazier, O H and Koneru, Srikanth},
title = {Effect of Preoperative Mitral Regurgitation on LVAD Outcomes in Patients with Elevated Pulmonary Vascular Resistance},
journal = {Cardiovascular Drugs and Therapy},
year = {2025},
doi = {10.1007/s10557-024-07581-1}
}
EUVIMED